Merck shares fall after analyst questions Gardasil sales
Shares of Merck fell more than 5 percent in afternoon trading after a UBS analyst said sales of Gardasil, a vaccine for the virus that can lead to cervical cancer, may be "flattening," according to Marketwatch.com.Analyst Roopesh Patel changed his rating on the New Jersey drugmaker from "buy" to "neutral," the website said.
Vaccines, and Gardasil in particular, have been a strong point for Merck in the past year. Merck is scheduled to issue its second-quarter earnings report on July 21.
Original Source : http://www.nj.com/business/index.ssf/2008/07/merck_shares_fall_after_analys.html
